此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Ongoing Lung Decline With Age Intensified Response (OLD AIR)

2026年6月30日 更新者:Samuel Cohen, MD、Cedars-Sinai Medical Center

A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)

This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).

研究概览

详细说明

This Phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the effects of fisetin, a naturally occurring flavonoid with senolytic properties, on pulmonary health in older adults. Aging and cigarette smoke exposure have both been associated with cellular senescence, a biological process characterized by the accumulation of dysfunctional cells that may contribute to progressive decline in organ function. The study investigates whether intermittent administration of fisetin can favorably influence lung physiology and biological markers associated with aging.

Participants will be randomized to receive either fisetin or placebo and will undergo a short-course treatment regimen using a "hit-and-run" approach intended to transiently target senescent cells. The study population includes older adults with and without a history of cigarette smoking to allow assessment across groups with differing risk for accelerated pulmonary aging.

Study procedures include clinical evaluations, pulmonary function testing, exercise-based assessments, electrocardiography, laboratory testing, and collection of blood and urine samples for analysis of biomarkers related to cellular senescence and aging. Participants will be followed over a two-week study period, during which safety, tolerability, and protocol feasibility will be assessed. The results of this pilot study are intended to inform the design of future trials evaluating senolytic therapies as potential interventions for age-related declines in lung function and health.

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • California
      • Los Angeles、California、美国、90048
        • 招聘中
        • Cedars-Sinai Medical Center
        • 接触:
        • 首席研究员:
          • Samuel Cohen, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Adults aged 60 years and older who are physically capable of participating in study procedures;
  • Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (<5-pound change);
  • No blood donation within 2 months before screening; absence of unstable chronic disease;
  • Willing to maintain baseline activity level throughout the study;
  • Body mass index <30 kg/m²;
  • Either a history of at least 10 pack-years of cigarette smoking or never-smoking status.

Exclusion Criteria:

  • Electrocardiogram (ECG) abnormalities, including prolonged QTc.
  • Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening.
  • Resting systolic blood pressure >160 mmHg or diastolic blood pressure >110 mmHg.
  • Known allergy or hypersensitivity to fisetin or any component of the study product.
  • Active malignancy, except non-melanoma skin cancer.
  • Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results.
  • Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation.
  • Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection.
  • History of diverticulitis or diverticulosis with gastrointestinal bleeding.
  • Current use of systemic corticosteroids.
  • Current use of warfarin.
  • Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements.
  • Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator.
  • Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments.
  • Unwillingness or inability to provide informed consent.
  • Pregnancy or breastfeeding.
  • Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Fisetin
Participants receive oral fisetin at approximately 20 mg/kg/day for 2 consecutive days on Days 1-2 and again on Days 8-9 using a senolytic "hit-and-run" dosing strategy.
Participants randomized to the experimental arm will receive oral fisetin capsules administered at a target dose of approximately 20 mg/kg/day for 2 consecutive days on Days 1-2 and again on Days 8-9. Fisetin will be supplied as 100 mg capsules and dosed according to body weight using a senolytic "hit-and-run" treatment approach.
安慰剂比较:Placebo
Participants receive matching placebo capsules administered on the same schedule as the fisetin arm (Days 1-2 and Days 8-9).
Participants randomized to the control arm will receive matching placebo capsules administered orally on the same schedule as the fisetin arm (Days 1-2 and Days 8-9). Placebo will be used to maintain blinding and permit comparison of efficacy and safety outcomes between treatment groups.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Forced Vital Capacity (FVC)
大体时间:Baseline and Day 14
Forced vital capacity measured by spirometry to assess lung function following treatment with fisetin versus placebo.
Baseline and Day 14
Forced Expiratory Volume in 1 Second (FEV1)
大体时间:Baseline and Day 14
Forced expiratory volume in one second measured by spirometry following treatment with fisetin versus placebo.
Baseline and Day 14
FEV1/FVC Ratio
大体时间:Baseline and Day 14
Ratio of FEV1 to FVC measured by spirometry following treatment with fisetin versus placebo.
Baseline and Day 14

次要结果测量

结果测量
措施说明
大体时间
6-Minute Walk Distance (6MWD)
大体时间:Baseline and Day 14
Change in distance walked during a standardized 6-minute walk test, with pulse oximetry monitoring before and after the test.
Baseline and Day 14
Peak Oxygen Uptake (VO₂)
大体时间:Baseline and Day 14
Change in peak oxygen uptake measured during cardiopulmonary exercise testing (CPET) as an assessment of exercise capacity and cardiopulmonary fitness.
Baseline and Day 14
Biomarkers of Cellular Senescence
大体时间:Baseline and Day 14
Change in circulating biomarkers associated with cellular senescence measured from blood samples collected before and after treatment.
Baseline and Day 14

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月17日

初级完成 (估计的)

2027年6月16日

研究完成 (估计的)

2027年7月15日

研究注册日期

首次提交

2026年6月24日

首先提交符合 QC 标准的

2026年6月24日

首次发布 (实际的)

2026年6月30日

研究记录更新

最后更新发布 (实际的)

2026年7月1日

上次提交的符合 QC 标准的更新

2026年6月30日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • STUDY00003866

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data collected during this study will not be made publicly available. De-identified aggregate study results may be reported in publications and presentations. Requests for additional data may be considered by the Principal Investigator on a case-by-case basis and in accordance with applicable institutional policies, participant consent, privacy regulations, and IRB requirements.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅